trending Market Intelligence /marketintelligence/en/news-insights/trending/ejdtxmkg4vkiobipbx4v_q2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Indivior secures court order to block Dr. Reddy's launch of Suboxone generic

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Indivior secures court order to block Dr. Reddy's launch of Suboxone generic

Indivior PLC secured a temporary restraining order from a district court in New Jersey that stops Dr. Reddy's Laboratories Ltd. from selling a generic version of Suboxone Film, Indivior's opioid addiction treatment.

The action comes a day after Dr. Reddy's received the U.S. Food and Drug Administration's approval to sell the generic. The agency granted approvals to Mylan NV unit Mylan Technologies Inc. and Dr. Reddy's unit Dr. Reddy's Laboratories SA to market the drug in multiple strengths.

The restraining order will remain in place pending a hearing on the preliminary injunction motion filed by Indivior. The motion will result in a hearing at the court where Indivior will seek to extend the cessation of launch activities by Dr. Reddy's pending the outcome of recently filed patent litigation against the company.

The U.S. District Court for the District of New Jersey is expected to hold the hearing on the preliminary injunction motion June 28.

Commenting on the matter, Indivior CEO Shaun Thaxter said the company will continue to pursue "all legal avenues against Dr. Reddy's to protect our Suboxone Film patent estate."